13F Holdings
中文EN

CPIX CUMBERLAND PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1087294 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY10.7%
TTM net income YoY2,167.1%
TTM EPS YoY1,962.5%
Revenue 3-yr CAGR-13.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-38.2%
Net margin273.7%
FCF margin-3.9%
EBITDA margin-33.6%

Returns

ROE139.5%
ROA76.6%
ROIC (approx.)-532.4%
Asset turnover0.28x

Leverage & solvency

Liabilities / assets36.6%
Debt / equity0.00x
Current ratio3.05x
Interest coverage-47.02x

Cash quality & payout

Operating cash flow / net income-0.01x
Accruals ratio77.6%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$44.52M$37.87M$39.55M$42.01M$35.99M
Cost of revenue$6.67M$6.59M$6.07M$9.12M$8.81M
Gross profit$37.85M$31.28M$33.49M$32.89M$27.17M
R&D expense$5.57M$4.82M$5.83M$6.69M$5.68M
SG&A expense$11.95M$11.13M$10.65M$10.18M$9.78M
Operating income-$2.79M-$6.43M-$9.55M-$5.70M-$7.68M
Interest expense$495,990$605,508$667,861$585,995$98,031
Pretax income-$2.81M-$6.47M-$6.28M-$5.58M-$5.56M
Income tax$40,256-$22,669$45,769$68,850$34,891
Net income-$2.84M-$6.48M-$6.28M-$5.57M-$3.51M
EBITDA$1.35M-$1.53M-$4.62M-$376,816-$3.07M
EPS (basic)-0.19-0.46-0.44-0.38-0.24
EPS (diluted)-0.19-0.46-0.44-0.38-0.24
Weighted avg. shares (diluted)14.85M14.06M14.30M14.56M14.90M
Balance sheet
Cash & equivalents$11.44M$17.96M$18.32M$19.76M$27.04M
Receivables$16.94M$11.70M$9.76M$13.16M$6.88M
Inventory$29,935$4.00M$4.61M$9.86M$8.43M
Current assets$37.06M$36.45M$35.71M$45.87M$45.69M
PP&E, net$264,724$277,365$367,903$284,039$442,635
Goodwill$914,000$914,000$914,000$914,000$882,000
Intangibles$53,621$17.97M$22.61M$30.59M$23.95M
Total assets$76.82M$75.58M$81.78M$92.93M$84.46M
Current liabilities$36.74M$31.62M$27.98M$28.58M$19.28M
Short-term debt$0$5.10M$0——
Total liabilities$52.28M$53.04M$52.52M$56.95M$41.86M
Shareholders' equity$24.88M$22.85M$29.60M$36.27M$42.81M
Shares outstanding14.96M13.95M14.12M14.37M14.74M
Cash flow statement
Operating cash flow$4.93M-$612,186$6.09M$8.45M$6.34M
Capital expenditure$97,903$66,461$281,268$102,148$103,532
Free cash flow$4.83M-$678,647$5.81M$8.35M$6.24M
Investing cash flow-$4.71M$57,842-$105,695-$13.67M-$501,893
Financing cash flow-$6.75M$196,904-$7.42M-$2.06M-$3.55M
Depreciation & amortization$4.15M$4.90M$4.94M$5.33M$4.61M
Stock-based compensation$408,320$301,895$365,040$447,503$741,867
Share buybacks$263,478$579,049$740,533$1.05M$1.39M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.